Drugs

Liraglutide and Gall Bladder Issues

In addition to glycemic control, liraglutide also promotes weight loss, which can be helpful in patients with obesity and type 2 diabetes. However, development of gallstones may be a common side effect in patients that are on liraglutide for the treatment of their type 2 diabetes. Read more

FDA Approves Oral Semaglutide for Type 2 Diabetes

The U.S. Food and Drug Administration (FDA) has approved a new medication, Rybelsus (semaglutide) oral tablets, for use in controlling blood sugar in adults with type 2 diabetes, along with diet and exercise. Rybelsus is the first medication in the glucagon-like peptide (GLP-1) receptor class that does not need to be injected to be approved […]

Two Diabetes Drugs Show Benefits for Nonalcoholic Fatty Liver Disease

Nonalcoholic fatty liver disease (NAFLD) often occurs in patients with type 2 diabetes. A recent study showed that the diabetes medications liraglutide and sitagliptin, in combination with metformin, can improve intrahepatic lipid and therefore benefit NAFLD. Read more

Metformin Lowers Risk of Dementia for Black Patients

Researchers found that metformin use was associated with a substantially lower risk for dementia among younger African-American patients with diabetes when compared with sulfonylurea, according to a recently published study. Read more

New Type of Diabetes Drug Performs Well in Phase 3 Trial

Imeglimin is the first in a new class of oral antidiabetic agents, the glimins. Imeglimin decreases hepatic glucose production, increases muscle glucose uptake, and improves pancreatic glucose-dependent insulin secretion. The drug performed well in combination with metformin in its latest trial. Read more

Remission of Type 2 Diabetes

The results of a major study show that intensive weight management strategies and drug therapy can achieve remission of type 2 diabetes. Patients who once suffered may be able to regain their previous quality of life and reduce their risk of secondary complications later down the line. Read more

FDA Approves Victoza for Treating Diabetes in Children

The U.S. Food and Drug Administration (FDA) has approved Victoza (liraglutide) injection for treatment of pediatric patients 10 years or older with type 2 diabetes. Victoza is the first non-insulin drug approved to treat type 2 diabetes in pediatric patients since metformin was approved for pediatric use in 2000. Victoza has been approved to treat […]

Old Malaria Drug May Help Manage Glucose

Hydroxychloroquine is an anti-inflammatory drug that is among the oldest prescribed drugs first used to treat malaria. Researchers have found it may help treat autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis (RA); now, researchers say it can also help with blood glucose management in diabetes. Read more

A Drug to Delay Type 1?

Scientists have reported a major breakthrough in treating type 1 diabetes: a drug that can delay the development of the disease in young people at high risk. The researchers found that 2 weeks of treatment with an experimental intravenous drug delayed development of type 1 diabetes by an average of about two years. Read more

Metformin Associated with B12 Deficiency, Cognitive Issues

A recent study found  that metformin use was associated with impaired cognitive performance and vitamin B12 deficiency. Vitamin B12 and calcium supplements may help to reduce metformin-induced vitamin B12 deficiency, and were associated with better cognitive outcomes in older patients taking metformin. Read more

Some Diabetes Drugs Linked to Genital Gangrene

The SGLT2 inhibitors class of diabetes drugs appear to increase the risk of gangrene of the genital area, a rare but potentially fatal side effect. The FDA found 55 cases of the condition, called Fournier gangrene, in people taking three common types of SGTL2 inhibitors, between March 2013 and January 2019. Read more

Prostrate Drugs May Increase Type 2 Risk

Results from a new study led by the University of Edinburgh and UCL suggests men taking the medicines dutasteride or finasteride to reduce the symptoms of prostate disease may be more likely to develop type 2 diabetes. Read more

Common Prostate Medications May Increase Diabetes Risk

Two widely used drugs for treating an enlarged prostate may increase the risk of developing type 2 diabetes. A study examined of two similar drugs, finasteride (Proscar) and dutasteride (Avodart), in 39,000 men; the 11-year study used 16,000 men taking tamsulosin (Flomax), a different type of drug for B.P.H., as controls. Compared with those using […]

Canagliflozin Study Stopped Early Due to Positive Results

Clinical trials are really stopped early, but the phase 3 trial of “Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation” a.k.a. CREDENCE, was halted early due to demonstration of significant heart and kidney benefits for canagflozin, (Invokana, Janssen Pharmaceuticals Inc.). Read more

Medications that can Affect Your Exercise

Many medications can potentially impact your ability to be physically active. Although most drugs do not affect exercise, several common nondiabetes medications do have potential effects on exercise, including statins, beta-blockers, diuretics, vasodilators, and blood thinners. Read more

Should People Who Don’t have Diabetes Take Metformin?

There’s been much recent discussion about whether taking the diabetes drug metformin has health benefits for people who don’t have diabetes. Some leading experts in diabetes medicine offer their opinions and recommendations on whether or not more people should be taking metformin. Read more

Diabetes Medications May Help Ward Off Alzheimer’s

Taking diabetes medication to treat type 2 diabetes may also help keep Alzheimer’s disease away. A recent study found that patients with untreated diabetes developed signs of Alzheimer’s disease 1.6 times faster than people who did not have diabetes. Read more

New Oral Drug for Type 2 Submitted to FDA

On March 20, 2019, Novo Nordisk announced the official submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the oral tablet semaglutide, a once-daily glucagon-like peptide-1 (GLP-1) analogue. In trials, oral semaglutide caused reductions in both HbA1c and body weight when compared to placebo. Read more

Metformin Safety in Chronic Kidney Disease

Metformin has not been well studied in patients with impaired kidney function, as it was considered unsafe for use in individuals with moderate or severe chronic kidney disease (CKD). However, the FDA has revised this position, and they have concluded that metformin can be used safely in patients with mild impairment in kidney function and […]

Schizophrenia and Diabetes

People with schizophrenia have a 20-year shorter lifespan than people without the condition, and diabetes is one cause of this shorter lifespan. Medications for schizophrenia can affect some patient’s with metabolic disturbances: increased weight gain, impaired glucose tolerance and new onset diabetes. Lifestyle risks are also involved, but the direct and indirect effects of the […]